Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial

BACKGROUND: Rabies kills around 60 000 people each year. ChAdOx2 RabG, a simian adenovirus-vectored rabies vaccine candidate, might have potential to provide low-cost single-dose pre-exposure rabies prophylaxis. This first-in-human study aimed to evaluate its safety and immunogenicity in healthy adu...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenkin, Daniel, Ritchie, Adam J, Aboagye, Jeremy, Fedosyuk, Sofiya, Thorley, Luke, Provstgaad-Morys, Samuel, Sanders, Helen, Bellamy, Duncan, Makinson, Rebecca, Xiang, Zhi Quan, Bolam, Emma, Tarrant, Richard, Lopez, Fernando Ramos, Platt, Abigail, Poulton, Ian, Green, Catherine, Ertl, Hildegund C J, Ewer, Katie J, Douglas, Alexander D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614839/
https://www.ncbi.nlm.nih.gov/pubmed/35907430
http://dx.doi.org/10.1016/S2666-5247(22)00126-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614839/
https://www.ncbi.nlm.nih.gov/pubmed/35907430
http://dx.doi.org/10.1016/S2666-5247(22)00126-4

Ejemplares similares